News of Note—Abzena invests in California, Catalent in China

Cancer in newspaper clipping
(Pixabay)

> Abzena is investing $20 million to add two manufacturing suites at the 500 liter and 2000 liter scale, at its manufacturing facility in San Diego, California. Release

> Catalent Pharma Solutions will invest $2.5 million in a second clinical supply facility in Shanghai, China, which will employ about 100 people when it opens in early 2019. Release

> The FDA is instituting new protocols to gather data from sterile injectable manufacturers in an effort to raise quality and avoid shortages. Release

> Dave Tudor, Ph.D., previously head of manufacturing strategy for GlaxoSmithKline, has been appointed managing director of the Medicines Manufacturing Innovation Centre, a collaboration among GSK, AstraZeneca, CPI and the University of Strathclyde in Scotland. Release

> For the first time in 30 years the U.S. will have a domestic supply of Iodine-131 (I-131), a critical radioisotope for diagnosing and treating thyroid cancer and hyperthyroidism. The supply is being produced by the University of Missouri. Release

Suggested Articles

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.

A Chinese OTC drugmaker gets the distinction of ringing in the new year as the first company to be slapped with an FDA warning letter.